Research programme: CR1-targeted vaccines - Elusys Therapeutics

Drug Profile

Research programme: CR1-targeted vaccines - Elusys Therapeutics

Latest Information Update: 14 Sep 2010

Price : $50

At a glance

  • Originator Elusys Therapeutics
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Infections

Most Recent Events

  • 14 Sep 2010 This programme is still in active development
  • 06 Dec 2007 Early research in Infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top